Nurse Practitioner, Family · Detroit, MI
NPI
1639653058
Since 2018
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
3901 Chrysler Dr Ste 4a
Detroit, MI, 48201
Phone (313) 966-7601
Groups this clinician bills Medicare through
Medicare paid, 2024
$1,438
27 services
Medicare patients, 2024
15
Average age 58
Drug cost, 2024
$1.8M
783 prescriptions
Company payments, 2025
$19.29
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Emily Delmotte was code 99214 (office e&m - established), 19 times for 14 patients. In total Emily Delmotte billed 27 services in 8 codes, and Medicare paid $1,438.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 19 | 14 | $54.02 | $1,026 |
By year: 2022 $3,207 for 53 services; 2023 $3,942 for 149 services; 2024 $1,438 for 27 services.
Medicare prescription drug claims, 2024
In 2024, the drug Emily Delmotte prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 84 prescriptions and refills. In total Emily Delmotte wrote 783 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 84 | 84 | 12 | $333K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 81 | 81 | Under 11 | $320K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 65 | 65 | Under 11 | $246K |
| Tivicay Dolutegravir Sodium | 63 | 63 | Under 11 | $177K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 59 | 59 | Under 11 | $211K |
| Juluca Dolutegravir/Rilpivirine | 42 | 42 | Under 11 | $140K |
| Prezcobix Darunavir/Cobicistat | 39 | 39 | Under 11 | $91K |
| Descovy Emtricitabine/Tenofov Alafenam | 38 | 38 | Under 11 | $81K |
| Darunavir Generic | 35 | 35 | Under 11 | $29K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 26 | 26 | Under 11 | $523 |
| Lamivudine-Zidovudine Lamivudine/Zidovudine | 23 | 23 | Under 11 | $1,804 |
| Isentress Raltegravir Potassium | 21 | 21 | Under 11 | $39K |
| Ritonavir Generic | 20 | 20 | Under 11 | $1,124 |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 18 | 18 | Under 11 | $945 |
| Famciclovir Generic | 14 | 14 | Under 11 | $6,518 |
Brand drugs: 529 claims; generic drugs: 254 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Emily Delmotte $19.29 ($19.29 in general payments such as food, travel and fees) from 1 company. The largest payer was Boston Scientific Corporation with $19.29.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 1 | $19.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.